Early Trajectory of Stroke Severity Predicts Long-Term Functional Outcomes in Ischemic Stroke Subjects

Results From the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times)

Tolulope T. Sajobi, PhD; Bijoy K. Menon, MD; Meng Wang, MSc; Oluwaseyi Lawal, MSc; Ashfaq Shuaib, MD; David Williams, MB, PhD; Alexandre Y. Poppe, MD; Tudor G. Jovin, MD; Leanne K. Casaubon, MD; Thomas Devlin, MD; Dar Dowlatshahi, MD; Chris Fanale, MD; Mark W. Lowerison, MSc; Andrew M. Demchuk, MD; Mayank Goyal, MD; Michael D. Hill, MD, MSc; and the ESCAPE Trial Investigators

Background and Purpose—The trajectory of neurological improvement after stroke treatment is clinically likely to be an important prognostic signal. We compared the accuracy of early longitudinal National Institutes of Health Stroke Scale (NIHSS) measurement versus other early markers of stroke severity post treatment in predicting subjects' 90-day stroke outcome.

Methods—Data are from the Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). Stroke severity was assessed at baseline, 1, 2, 5, 30, and 90 days. Subjects' functional outcome was assessed using the modified Rankin Scale at baseline, 30 days, and 90 days. Group-based trajectory model was used to identify distinct subgroups of longitudinal trajectories of NIHSS measured over the first 2, 5, and 30 days. The accuracy of baseline NIHSS, infarct volume, 24-hour change in NIHSS, infarct volume, and disease severity trajectory subgroups in predicting 90-day stroke outcome were assessed using logistic regression analysis.

Results—Group-based trajectory model of the 2-day longitudinal NIHSS data revealed 3 distinct subgroups of NIHSS trajectories—large improvement (41.6%), minimal improvement (31.1%), and no improvement (27.3%) subgroups. Individuals in the large improvement group were more likely were more likely to exhibit good outcomes after 90 days than those in the minimal improvement or no improvement subgroup. Among candidate predictors, the 2-day trajectory subgroup variable was the most accurate in predicting 90-day modified Rankin Scale at 84.5%.

Conclusions—Early trajectory of neurological improvement defined by 2-day longitudinal NIHSS data predicts functional outcomes with greater accuracy than other common variables.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335.

(Stroke. 2017;48:105-110. DOI: 10.1161/STROKEAHA.116.014456.)

Key Words: National Institutes of Health (U.S.) ▪ prognosis ▪ stroke ▪ thrombolytic therapy ▪ tomography, x-ray computed tomography

See related article, p 6.

Initial stroke severity is a primary determinant of clinical outcome among subjects with acute ischemic stroke. Several measures of stroke severity have been developed and include the National Institutes of Health Stroke Scale (NIHSS) scale,1,2 the Canadian Neurological Scale,3 Scandinavian Stroke Scale,4,5 and the European Stroke Scale6 among others. Although baseline measures of stroke severity are always reported and represent the best pretreatment measure to

Received August 10, 2016; final revision received August 10, 2016; accepted September 26, 2016.

From the Department of Community Health Sciences and O’Brien Institute for Public Health (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Clinical Neurosciences (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Radiology (B.K.M., A.M.D., M.G., M.D.H.), Hotchkiss Brain Institute (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Physiology and Pharmacology (O.L.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland (D.W.); Department of Clinical Neurosciences, Universite de Montreal and Hospital Notre Dame, Quebec, Canada (A.Y.P.); University of Pittsburgh Medical Center, PA (T.G.J.); University Health Network and Toronto Western Hospital, Ontario, Canada (L.K.C.); Erlanger Medical Center, Chattanooga, TN (T.D.); University of Ottawa Hospital, Ontario, Canada (D.D.); and Swedish Medical Centre, Englewood, CO (C.F.).

Guest Editor for this article was Ajay K. Wakhloo, MD, PhD.

Correspondence to Michael D. Hill, MD, MSc, 3330 Hospital Dr NW, Rm 2939, University of Calgary, Calgary, Alberta T2N 4N1, Canada. E-mail michael.hill@ucalgary.ca

© 2016 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.116.014456

105
predict outcome, other markers of stroke severity that include post-treatment information may be better predictors of
clinical and functional outcomes. For example, change in NIHSS, infarct volume, and 24-hour NIHSS have been shown to be
the strongest predictors of subjects’ 90-day stroke outcomes.\textsuperscript{7-9} Repeated assessments of stroke severity are routinely col-
lected in stroke research studies providing an opportunity to
assess longitudinal data on subjects’ postdischarge functional
outcomes.

We investigated the prognostic utility of the trajectory of
stroke severity change using repeat assessments of stroke
severity within 48 hours of stroke symptom onset in predict-
ing subjects’ 90-day functional outcome defined by the modi-
ified Rankin Scale (mRS) score. Specifically, we compare the
predictive performance of several early markers of stroke
severity, including 24-hour NIHSS, change in NIHSS from
baseline to 24 hours, and latent NIHSS trajectories in predict-
ing 90-day functional outcomes in subjects enrolled in the
ESCAPE trial (Endovascular Treatment for Small Core and
Anterior Circulation Proximal Occlusion With Emphasis on
Minimizing CT to Recanalization Times).

Study Design
The ESCAPE trial was an investigator initiated multicenter,
prospective, randomized, open-label controlled trial with
blinded endpoint assessment (PROBE) design assessing the
additional benefit of modern endovascular treatment when
compared with guideline-based standard of care. Participants
were assigned, in a 1:1 ratio, to receive endovascular treatment
plus guideline-based care (intervention group) or guideline-
based care alone (control group). The trial screened subjects
fulfilling clinical eligibility criteria if they presented within 12
hours of stroke symptom onset and then included them only
if they met neurovascular imaging criteria. All subjects had
standard assessment for demographics, medical history, previ-
ous medications, baseline laboratory tests, and stroke severity
(defined by the NIHSS score). The trial enrolled 316 subjects
with 165 subjects randomized to intervention arm and 150
subjects randomized to control arm, and 1 excluded due to
improper consent procedures. After randomization, NIHSS
was assessed within the first 8 hours, at 24 hours, 48 hours,
5 days, 30 days, and 90 days. The primary outcome was the
mRS at 90 days after randomization.\textsuperscript{10,11}

Group-based trajectory modeling (GBTM) was used to
identify subject subgroups with distinct longitudinal trajec-
tories of stroke severity, as measured by the NIHSS over
a 48-hour, 5-day, and 30-day period after randomization.
GBTM is a flexible methodology that models heterogene-
ity in longitudinal trajectory of individuals, while identify-
ing latent (ie, unobserved) subgroups of individuals with
the similar longitudinal trajectories. GBTM estimates sub-
ject-specific posterior probability of belonging to different
latent subgroups. This methodology simultaneously imple-
ments several regression models through maximization of a
likelihood that combines the information from all models.
Specifically, the probability of belonging to each potential
adherence group is modeled as a simple multinomial logis-
tic regression with no predictors (only an intercept for each

Results
There were 4 repeated assessments of NIHSS over 48 hours
and 6 repeated measurements over 30 days post randomization.
The GBTM of the 48-hour longitudinal NIHSS data revealed 3 distinct subgroups of subjects. Specifically, 41.6% of the subjects had consistently large improvement 31.1% of the subjects had minimal improvement, whereas 27.3% had no improvement in NIHSS scores over the 48-hour period (Figure 1). Each trajectory subgroup had an average posterior probability of >0.9 indicating excellent grouping. When the 5- and 30-day NIHSS longitudinal data were used (ie, 5 and 6 repeated assessments of NIHSS, respectively), the GBTM revealed similar number of distinct trajectory groups (Figures 2 and 3).

Table 1 describes the demographic, clinical, and imaging characteristics of subjects in each of the three trajectory subgroups. Subjects in the large improvement subgroup were likely to be younger with lower baseline NIHSS, who mostly received endovascular treatment and intravenous alteplase. There were no significant differences among subjects in the trajectory subgroups with respect to sex, smoking status, hypertension, diabetes mellitus, use of general anesthesia, and work flow times.

Table 2 describes the univariate contribution of baseline NIHSS, infarct volume, delta NIHSS, 24-hour NIHSS, and trajectory grouping variable in predicting 90-day mRS. Specifically, we found that baseline NIHSS (model 1) was least discriminative predictive of 90-day mRS (AUC=66.6%). Final infarct volume (model 2) had the second least discriminatory power in predicting 90-day mRS (AUC=73.1%), whereas 2- and 5-day trajectory grouping variables (models 5 and 6) were most discriminative (but not different between them) in predicting 90-day mRS (AUC=84.5% and 85.8%), respectively.

Although the 24-hour NIHSS score and change in 24-hour NIHSS had slightly lower AUCs than trajectory group variable, the 95% confidence intervals for the AUCs of these markers of stroke severity overlapped, suggesting that are no significant differences in predictive performance of these markers of stroke severity in predicting 90-day mRS. An examination of the results predictive performance of these markers for the 5- and 30-day longitudinal NIHSS data revealed that there is a negligible improvement in the predictive performance of the trajectory variable when compared with the trajectory grouping variable derived from the 48-hour data.

Table 3 describes the results from the multiple logistic regression analyses of the relationship between early clinical prognostic markers and 90-day stroke outcomes after adjusting for subjects’ baseline characteristics such as sex, age, Alberta Stroke Program Early CT Score, type of treatment received, and baseline occlusions (ie, models 1–6). For each model, the variance inflation factor was <4, indicating that there was no evidence of multicollinearity among all the explanatory variables. Overall, all models had high discriminatory performance in predicting mRS after adjusting for subjects’ baseline characteristics. Although there was ≈10% improvement in the predictive performance of baseline NIHSS (≈10% increase in AUC) after adjusting for baseline

![Figure 1](http://stroke.ahajournals.org/) Group-based trajectory analysis of longitudinal National Institutes of Health Stroke Severity (NIHSS) scores over a 48-h period postbaseline. Group 1=large improvement in NIHSS; group 2=minimal improvement in NIHSS; and group 3=no improvement in NIHSS.

![Figure 2](http://stroke.ahajournals.org/) Group-based Trajectory analysis of longitudinal National Institutes of Health Stroke Severity (NIHSS) scores over a 5-d period postbaseline. Group 1=large improvement in NIHSS; group 2=minimal Improvement in NIHSS; group 3=no improvement in NIHSS.

![Figure 3](http://stroke.ahajournals.org/) Group-based trajectory analysis of longitudinal National Institutes of Health Stroke Severity (NIHSS) scores over a 30-d period postbaseline. Group 1=large improvement in NIHSS; group 2=minimal improvement in NIHSS; group 3=no improvement in NIHSS.
characteristics, there was negligible improvement in predictive performance of change in NIHSS (model 3*), NIHSS at 24 hours (model 4*), and trajectory grouping variable in predicting 90-day mRS (models 5* and 6*). The model with baseline NIHSS had the smallest predictive accuracy. Greater discriminatory power was observed for models using a post-baseline marker of stroke severity concomitant with a smaller marginal effect of treatment in predicting 90-day mRS. For

### Table 1. Characteristics of Study Participants by 2-Day NIHSS Trajectory Subgroups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Large Improvement (n=135)</th>
<th>Minimum Improvement (n=113)</th>
<th>No Improvement (n=67)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>68.1 (19.5)</td>
<td>73.1 (19.7)</td>
<td>73.5 (21.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>69 (51.5)</td>
<td>62 (54.9)</td>
<td>34 (50.8)</td>
<td>0.80</td>
</tr>
<tr>
<td>Baseline occlusions (ICA)</td>
<td>21 (15.6)</td>
<td>31 (27.4)</td>
<td>32 (47.8)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

**ASPECTS**

| 0–5                     | 1 (0.8)                  | 3 (2.7)                     | 7 (10.6)              | <0.01   |
| 6–7                     | 11 (8.3)                 | 20 (18.2)                   | 14 (21.2)             |         |
| 8–10                    | 112 (90.9)               | 87 (79.1)                   | 45 (68.2)             |         |
| Treatment (endovascular, %)| 87 (64.4)            | 56 (49.6)                   | 22 (32.8)             | <0.01   |
| IV alteplase (yes, %)   | 107 (79.3)               | 76 (67.3)                   | 54 (80.6)             | 0.05    |

Smoking status

| Never smoked            | 67 (49.6)                | 60 (53.1)                   | 32 (50.0)             | 0.24    |
| Current smoker          | 32 (23.7)                | 25 (22.9)                   | 8 (12.5)              |         |
| Past smoker             | 36 (26.7)                | 28 (26.0)                   | 24 (37.5)             |         |
| IV-IA tx (mother ship), n (%)| 70 (51.9)            | 46 (40.7)                   | 37 (55.2)             | 0.10    |
| Anticoagulation, n (%)  | 22 (16.3)                | 19 (16.8)                   | 8 (11.9)              | 0.66    |
| Hypertension, n (%)     | 86 (63.7)                | 82 (72.6)                   | 45 (67.2)             | 0.33    |
| Atrial fibrillation, n (%)| 48 (35.6)              | 49 (43.4)                   | 24 (35.8)             | 0.40    |
| Onset to tPA time       | 117.5 (76.0)             | 115.0 (65.0)                | 108.0 (76.0)          | 0.86    |
| Systolic blood pressure | 143.0 (35.0)             | 149.0 (31.0)                | 146.0 (41.0)          | 0.09    |
| Glucose                 | 6.6 (1.9)                | 6.9 (1.9)                   | 6.7 (2.1)             | 0.14    |
| ED to CT, min, median (IQR) | 19.0 (18.0)         | 18.0 (18.0)                 | 19.0 (19.0)           | 0.84    |
| Stroke onset to rand, median (IQR) | 174 (158)           | 174 (195)                   | 164 (135)             | 0.74    |
| Death at 90 d, n (%)    | 4 (3.0)                  | 12 (10.8)                   | 29 (43.9)             | <0.01   |
| NIHSS at baseline, median (IQR) | 13.0 (8.0)          | 17.5 (6.5)                  | 17.0 (8.0)            | <0.01   |

ASPECTS indicates Alberta Stroke Program Early CT Score; CT, computed tomography; ED, emergency department; ICA, internal carotid artery; IQR, interquartile range; IV, intravenous; IV-IA, intravenous-intra-arterial; NIHSS, National Institutes of Health Stroke Severity; and tPA, tissue-type plasminogen activator.

### Table 2. Unadjusted Effects (Odds Ratio [95% CI]) of Markers of Stroke Severity on Patients’ 90-Day Modified Rankin Scale Outcomes

<table>
<thead>
<tr>
<th>Marker of Stroke Severity</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
<th>Model 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline NIHSS</td>
<td>0.89 [0.85–0.93]</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Infarct volume</td>
<td>...</td>
<td>0.98 [0.97–0.99]</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>ΔNIHSS (baseline to 24 h)</td>
<td>...</td>
<td>...</td>
<td>0.85 [0.81–0.90]</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>NIHSS at 24 h</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.82 [0.78–0.86]</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>2-d trajectory group 2 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.09 [0.05–0.17]</td>
<td>...</td>
</tr>
<tr>
<td>2-d trajectory group 3 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.01 [&lt;0.01–0.04]</td>
<td>...</td>
</tr>
<tr>
<td>5-d trajectory group 2 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.133 [0.07–0.24]</td>
<td>...</td>
</tr>
<tr>
<td>5-d trajectory group 3 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.002 [&lt;0.001–0.03]</td>
<td>...</td>
<td></td>
</tr>
<tr>
<td>Predictive accuracy (AUC%, CI)</td>
<td>66.6 [60.4–72.8]</td>
<td>73.1 [67.5–78.6]</td>
<td>76.0 [70.6–81.5]</td>
<td>82.7 [77.9–87.6]</td>
<td>84.5 [80.6–88.4]</td>
<td>85.8 [82.1–89.5]</td>
</tr>
</tbody>
</table>

Model 1 is logistic regression with baseline NIHSS as predictor; model 2 is logistic regression with infarct volume; model 3 is logistic regression with ΔNIHSS as predictor; model 4 is logistic regression with NIHSS at 24 h as predictor; model 5 is logistic regression with 2-day trajectory grouping variable as predictor; model 6 is logistic regression with 5-day trajectory grouping variable as predictor. AUC indicates area under the receiver operating characteristic; CI, confidence interval; and NIHSS, National Institutes of Health Stroke Severity Scale.
example, the model with baseline NIHSS (model 1*) had the smallest predictive accuracy, but showed the largest treatment effect size (odds ratio, 3.38; \( P < 0.01 \)). In contrast, the model with 2-day trajectory subgroup variable as a marker of stroke severity (model 5*) had the highest predictive accuracy (AUC=88.5%) but the smallest treatment effect size (odds ratio, 2.04; \( P < 0.05 \)).

**Discussion**

Early postbaseline markers of stroke severity in the first 48 hours can accurately predict subject outcomes among those treated with endovascular therapy. We show that latent trajectory subgroups based on longitudinal NIHSS scores collected during the first 48 hours are better predictors of 90-day outcome than other markers of stroke severity.

A critical distinction in comparing trajectory groups to baseline measures of severity is that the trajectory group necessarily includes the impact of the treatment effect in influencing trajectories of stroke severity because trajectory groups include data derived after randomization and treatment. The identification of the 48-hour trajectory, incorporating just 4 measures (baseline, 2–8 hours, 24 hours, 48 hours) as the most powerful predictor of outcome is directly relevant to quality improvement measurement strategies in stroke and to future trials of acute stroke therapy. The results are consistent with the findings of the NINDS tPA Study (National Institutes of Neurological Disorders and Stroke Tissue Plasminogen Activator) group that identified the binary outcome of NIHSS 0 to 2 at 24 hours as the most powerful predictor of intravenous alteplase treatment effect.8

Although the predictive performance of 5- and 30-day repeated assessments of stroke severity were also investigated, the improvement in predictive power of the repeated assessments beyond the first 48 hours were negligible. Although it has been established that rapid treatment of stroke subjects often yields good clinical outcomes, early

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
<th>Model 5</th>
<th>Model 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female vs male)</td>
<td>1.22 [0.73–2.06]</td>
<td>1.53 [0.88–2.64]</td>
<td>1.39 [0.79–2.43]</td>
<td>1.37 [0.75–2.50]</td>
<td>1.46 [0.78–2.76]</td>
<td>1.46 [0.78–2.76]</td>
</tr>
<tr>
<td>Age, y</td>
<td>0.96 [0.94–0.98]</td>
<td>0.95 [0.93–0.97]</td>
<td>0.95 [0.93–0.97]</td>
<td>0.96 [0.94–0.98]</td>
<td>0.97 [0.95–0.99]</td>
<td>0.97 [0.95–0.99]</td>
</tr>
<tr>
<td>Intravenous alteplase (yes vs no)</td>
<td>0.80 [0.44–1.44]</td>
<td>0.90 [0.49–1.64]</td>
<td>0.61 [0.32–1.15]</td>
<td>0.55 [0.27–1.11]</td>
<td>0.56 [0.27–1.15]</td>
<td>0.53 [0.25–1.12]</td>
</tr>
<tr>
<td>Baseline occlusion (MCA vs ICA)</td>
<td>1.44 [0.78–2.68]</td>
<td>1.23 [0.64–2.36]</td>
<td>1.63 [0.85–3.13]</td>
<td>0.88 [0.42–1.81]</td>
<td>0.71 [0.33–1.51]</td>
<td>0.68 [0.31–1.51]</td>
</tr>
<tr>
<td>ASPECTS (0–5 ref)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6–7</td>
<td>0.80 [0.13–5.14]</td>
<td>0.75 [0.11–5.33]</td>
<td>0.67 [0.11–4.00]</td>
<td>0.29 [0.04–1.91]</td>
<td>0.43 [0.06–3.37]</td>
<td>0.29 [0.03–2.81]</td>
</tr>
<tr>
<td>8–10</td>
<td>1.59 [0.29–8.85]</td>
<td>0.78 [0.13–4.88]</td>
<td>1.23 [0.24–6.27]</td>
<td>0.48 [0.09–2.65]</td>
<td>0.47 [0.07–3.17]</td>
<td>0.44 [0.06–3.45]</td>
</tr>
<tr>
<td>Baseline NIHSS</td>
<td>0.91 [0.87–0.96]*</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Infarct volume</td>
<td>...</td>
<td>0.98 [0.97–0.99]*</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>ΔNIHSS</td>
<td>...</td>
<td>...</td>
<td>0.85 [0.81–0.90]*</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>NIHSS at 24 h</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.83 [0.78–0.87]*</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>2-d trajectory group 2 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.10 [0.05–0.19]*</td>
<td>...</td>
</tr>
<tr>
<td>2-d trajectory group 3 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.01 [&lt;0.01–0.04]*</td>
<td>...</td>
</tr>
<tr>
<td>5-d trajectory group 2 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.13 [0.06–0.25]*</td>
<td>...</td>
</tr>
<tr>
<td>5-d trajectory group 3 vs group 1</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>0.002 [&lt;0.001–0.03]*</td>
<td>...</td>
</tr>
<tr>
<td>Predictive accuracy (AUC%–95% CI)</td>
<td>76.6 [77.0–86.4]</td>
<td>81.7 [77.0–86.4]</td>
<td>82.4 [77.6–87.1]</td>
<td>85.8 [81.5–90.1]</td>
<td>88.6 [85.0–92.2]</td>
<td>89.4 [85.9–92.9]</td>
</tr>
<tr>
<td>Hosmer–Lemeshow test statistic</td>
<td>0.73</td>
<td>0.51</td>
<td>0.17</td>
<td>0.57</td>
<td>0.85</td>
<td>0.87</td>
</tr>
</tbody>
</table>

Model 1 is logistic regression with baseline NIHSS as predictor; model 2 is logistic regression with infarct volume as predictor; model 3 is logistic regression with ΔNIHSS as predictor; model 4 is logistic regression with NIHSS at 24 hours as predictor; model 5 is logistic regression with 2-day trajectory grouping variable as predictor; model 6 is logistic regression with 5-day trajectory grouping variable as predictor. ASPECTS indicates Alberta Stroke Program Early CT Score; AUC, area under the receiver operating characteristic; CI, confidence interval; ICA, internal carotid artery; MCA, middle cerebral artery; ΔNIHSS, 24-hour change in NIHSS; and NIHSS, National Institutes of Health Stroke Severity Scale.

*\( P < 0.05 \).
repeat assessment of stroke severity can be useful for developing appropriate prognostic risk determination tools that aid clinical decision making after stroke treatment. This technique may be considered for single acute treatments and potentially as a surrogate outcome in acute ischemic stroke trials.

Sources of Funding
The ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times) was sponsored by the University of Calgary. Covidien Inc. (now Medtronic LLC) provided major funding through an unrestricted grant to the University of Calgary. Additional active and in-kind support for the trial is from a consortium of funding public and charitable sources (Heart & Stroke Foundation Canada, Alberta Innovates Health Solutions, Alberta Health Services, Canadian Institutes for Health Research through the CSPIN Network) and the University of Calgary (Hotchkiss Brain Institute, Department of Clinical Neurosciences, Department of Radiology, and Calgary Stroke Program).

This analysis of the data was not specifically funded.

Disclosures
Drs. Hill, Goyal, and Demchuk report grants from Medtronic LLC (Covidien) as described above for the ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). Drs. Hill and Demchuk report support from the Heart & Stroke Foundation of Alberta that was used for the ESCAPE trial. The other authors report no conflicts.

References
Early Trajectory of Stroke Severity Predicts Long-Term Functional Outcomes in Ischemic Stroke Subjects: Results From the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times)

the ESCAPE Trial Investigators

Stroke. 2017;48:105-110; originally published online December 6, 2016; doi: 10.1161/STROKEAHA.116.014456

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/48/1/105

An erratum has been published regarding this article. Please see the attached page for:
http://stroke.ahajournals.org//subscriptions/

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
Correction to: Early Trajectory of Stroke Severity Predicts Long-Term Functional Outcomes in Ischemic Stroke Subjects: Results From the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times)

In the article by Sajobi et al, “Early Trajectory of Stroke Severity Predicts Long-Term Functional Outcomes in Ischemic Stroke Subjects: Results From the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times),” which published online ahead of print December 6, 2016, and appeared in the January 2017 issue of the journal (Stroke. 2017;48:105–110. DOI: 10.1161/STROKEAHA.116.014456), a correction is needed.

On page 105, Dr William’s affiliation, “Royal College of Physicians in Ireland and Beaumont Hospital, Dublin, Ireland,” has been changed to read “Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.”

This correction has been made to the current online version of the article, which is available at http://stroke.ahajournals.org/content/48/1/105.